Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR1B | P28222 | 8/20 | 0.44 |
| ▸ | HTR1D | P28221 | 2/20 | 0.43 |
| ▸ | PDE5A | O76074 | 3/20 | 0.42 |
| ▸ | PDE4A | P27815 | 3/20 | 0.42 |
| ▸ | PDE4B | Q07343 | 3/20 | 0.42 |
| ▸ | PDE4C | Q08493 | 3/20 | 0.42 |
| ▸ | PDE4D | Q08499 | 3/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | CNR2 | P34972 | 2/20 | 0.41 |
| ▸ | CNR1 | P21554 | 1/20 | 0.41 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.39 |
| ▸ | HRH1 | P35367 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4720942 | 0.94 | HTR1B (0.41) | HTR1BHTR1DPDE5APDE4APDE4B | |
| SCHEMBL4723591 | 0.89 | ENPP1 (0.42) | HTR1BPDE5A | |
| SCHEMBL4723685 | 0.82 | ABCG2 (0.43) | GAATDP1CNR2 | |
| SCHEMBL4720474 | 0.81 | CYP1A2 (0.42) | HTR1BPDE5APDE4APDE4BPDE4C | |
| SCHEMBL4722874 | 0.78 | HTR1B (0.45) | HTR1BHTR1DGAATDP1L3MBTL1 | |
| SCHEMBL4724583 | 0.75 | PDE5A (0.37) | PDE5APDE4APDE4BPDE4CPDE4D | |
| SCHEMBL4767284 | 0.74 | HTR1B (0.46) | HTR1BHTR1DGAATDP1L3MBTL1 | |
| SCHEMBL1004658 | 0.73 | HTR1B (0.73) | HTR1BHTR1DCNR2CNR1SLC6A4 | |
| SCHEMBL4721628 | 0.72 | HTR1B (0.47) | HTR1BHTR1DPDE5APDE4APDE4B | |
| SCHEMBL5492669 | 0.71 | BCHE (0.40) | GAATDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080176857-A1 | 4-Piperazinnylthieno[2,3-d]Pyrimidine Compounds as Platelet Aggregation Inhibitors | PFIZER INC. | 2008-07-24 | — | — | US | disclosed |
| EP-1874780-A1 | 4-PIPERAZINYLTHIENO[2,3-D]PYRIMIDINE COMPOUNDS AS PLATELET AGGREGATION INHIBITORS | Pharmacia & Upjohn Company LLC (US) | 2008-01-09 | — | — | EP | disclosed |
| WO-2006100591-A1 | 4-PIPERAZINNYLTHIENO [2,3-D] PYRIMIDINE COMPOUNDS AS PLATELET AGGREGATION INHIBITORS | PHARMACIA & UPJOHN COMPANY LLC (US) | 2006-09-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080176857-A1 | 4-Piperazinnylthieno[2,3-d]Pyrimidine Compounds as Platelet Aggregation Inhibitors | TBXA2R, P2RY4, PF4 | HTR1B 111/4885HTR1D 94/4885PDE5A 269/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.